#Sweden #Stockholm #Sobi #Olezarsen #Tryngolza

Introduction

In a recent analysis presented at the European Atherosclerosis Society 2026 Congress held in Athens, Greece, Sobi® (Swedish Orphan Biovitrum AB) announced groundbreaking findings regarding Tryngolza® (olezarsen), a drug aimed at treating severe hypertriglyceridemia (sHTG). The results indicate a dramatic 85% reduction in the risk of acute pancreatitis events and a 66% decrease in triglyceride levels for patients struggling with this condition. This study marks a significant advancement in the field of metabolic health and diabetes management.

Background on Severe Hypertriglyceridemia

Severe hypertriglyceridemia is characterized by triglyceride levels reaching 880 mg/dL or more, which is considered a medical emergency due to the heightened risk of developing acute pancreatitis—a condition known for causing debilitating pain and often requiring hospitalization. Current treatment methods are not consistently effective in lowering triglyceride levels or alleviating risks for all patients with sHTG.

Trial Overview

The analysis involved a pooled subgroup from the pivotal Phase 3 CORE and CORE2 trials, encompassing a total of 455 patients with dangerously high triglyceride levels. Within just six months, those treated with olezarsen exhibited a substantial placebo-adjusted reduction in triglycerides, with the 80 mg dosage resulting in a 66% drop, while the 50 mg variant led to a 59% reduction. Remarkably, 85% of those administered olezarsen successfully achieved triglyceride levels below the critical threshold of 10 mmol/L.

Clinical Implications

According to Børge Nordestgaard, Professor and Chief Physician at Copenhagen University Hospital, the implications of these findings are substantial. Patients with triglyceride levels above 10 mmol/L face a fourfold increased risk of acute pancreatitis, which escalates as triglyceride levels rise. This analysis suggests that olezarsen can play a vital role in preventive healthcare strategies targeting at-risk populations. As noted by Lydia Abad-Franch, MD, olezarsen could be pivotal in managing disease progression for individuals vulnerable to acute pancreatitis.

Additional Findings

Apart from reducing the incidence of pancreatitis, the study results, presented by Dr. Andre Zimerman, also showed that olezarsen significantly lowered remnant cholesterol by 64% and decreased non-HDL cholesterol by 35%. The average reduction in acute pancreatitis events was approximately 12 events per 100 patient-years, indicating that treating just nine individuals for a year could potentially prevent one such event.

Regulatory Developments

Recently, the European Medicines Agency approved an extension application for olezarsen in treating adults with sHTG. Additionally, the U.S. FDA has accepted it for a supplemental new drug application targeting patients with triglyceride levels of 500 mg/dL and above, highlighting the growing recognition of olezarsen's potential in clinical practice.

Conclusion

Overall, the findings from these studies add to the increasing body of evidence suggesting that Tryngolza® has a strong role in managing sHTG and could significantly help in preventing serious complications like acute pancreatitis. As the prevalence of this condition rises globally, efforts to implement innovative therapies like olezarsen will be crucial for improving patient outcomes and reducing healthcare burdens associated with pancreatitis.

For more information about Tryngolza and the potential it holds for patients battling severe hypertriglyceridemia, visit the official Sobi website. Further updates regarding clinical studies and regulatory approvals will be crucial for patients and healthcare providers alike as they navigate treatment options for this serious condition.